Abstract
Introduction

Alzheimer's disease (AD) is characterized by adult-onset progressive dementia associated with cerebral cortical atrophy, ␤-amyloid plaque formation and intraneuronal neurofibrillary tangles
. About 75% of AD cases are classified as sporadic, which means they occur in people with no history of the condition in their family. All sporadic AD begins after age 65, 
and the risk of developing this condition increases as a person gets older.
Although AD usually appears in people older than age 65 , less common forms of the disease appear earlier in adulthood and are familial [3] . Familial AD can be divided into early-onset disease (symptoms begin before age 65) [3] . In this sense, there are hints of a genetic association of type 2 AD with polymorphisms in the 4 allele, of the apoliprotein E gene (ApoE), linking A␤ accumulation and deposition with the function of very low-density lipoproteins (VLDLs) [4] [5] [6] [7] . For ApoE-4, odds ratios were 11.8 and 21.8 for Caucasian and Asian population-based data on systematic meta-analysis of genetic association studies [8] . This [14, 15] , plants [16] and mice [17] [18] and experimentally [14, 19] [20] . Although there are several reports using metabolomic approaches as diagnostic tools both in biological fluids [21] and human beings in vivo [22, 23] 
and late-onset disease (symptoms begin after age 65). The different early-onset AD subtypes are clinically indistinguishable and can be classified on the basis of underlying genetic mechanisms as: AD type 1, 3 and 4 [3]. The human mutations associated with familial AD are strongly correlated to dysfunctional metabolism of ␤-amyloid precursor protein (APP) in the brain of affected individuals to produce an accumulation of amyloid-␤ peptide (A␤ peptide) and soluble amyloid precursor protein (sAPP) leading to the formation of amyloid plaques. Thus, amyloid-␤ (A4) precursor protein (APP) gene mutations cause type 1 AD (10-15% of all early-onset familial AD cases) while mutations in two processing APP genes, called presenilin 1 and 2, account for type 3 AD (70% of all early-onset AD) and for type 4 (5% of all early-onset AD), respectively. Type 2 is classified as late-onset familial AD. Although the cause of these cases is unknown, genetic changes are likely to play a role
Metabolomics of Alzheimer's disease
In the last few years, there have been a few reports about the use of NMR spectroscopy in the study of AD diseases in both human beings [26] and animal models of AD [27] . 1 [28, 29] . NAA is synthesized under normal conditions in the mitochondria of neurons, but not in glial cells [30] . NAA is early detected and therefore it might be useful for the assessment of neuroprotective treatment in AD [24] . [34] . Based on these, and other findings, it has been suggested that 'the application of biofluid based metabolomics in neuroscience will provide many opportunities to produce real benefit for sufferers of neurological disorders' [35] . While it may prove tricky to apply biofluid-based metabolomic analysis to neurosciences in a general manner, the brain remains the most accessible organ for application of MRS in vivo. [27, 36] . Marjanska and collaborators [36] working with APP-PS1 mice (which co-express mutated human presenilin 1 and APP) also found a reduction in NAA and glutamate and an increase in myo-inositol with age in the mutant mice. These authors take into account the metabolic changes that occur during normal aging [37] , which should not be neglected.
H-MRS is the most common NMT technique, because of its wide availability on clinical settings. In the in vivo spectra at low field (1.5 T of most reports in human beings) a few metabolites can be easily detected (Fig. 1). These include N-acetylaspartate (NAA) considered as a marker of neuronal density and integrity
Studies in animal models of AD
The only work using pattern recognition techniques is the one by von Kienlin and collaborators based on the transgenic mouse line PS2APP [38] [38] . [39] . Since then, numerous papers [44] 
Cheng and collaborators showed that HR-MAS has potential applications in experimental and clinical neuropathological investigations and that it could provide with a rational basis for the interpretation of in vivo MRS
. The Drosophila model of AD will take advantage of the previous knowledge, speed and statistical advantages of genetic screens in flies. In addition, the shorter animal cycles of flies and the absence of problems due to variability of metabolite concentrations that often is reported in different strains of mice will accelerate our understanding of AD.
Human studies
As early as 1995, pioneering work by Ross and collaborators reported that AD patients had lower levels of NAA [26] . This has been confirmed since by several groups in different brain regions [45] [46] [47] , although this feature is not specific of AD, as in almost every neurodegenerative disease examined to date there is extensive NAA loss in the region of the brain affected by the pathology [31] . NAA myo-inositol (mI) ratio is able to differentiate AD from non-AD patients [48] , this being related to a decrease in NAA but also to an increase in myo-inositol in AD post-mortem analysis [49, 50] . The biological significance of these myo-inositol changes is unknown so far. Kantarci and collaborators showed an increase in choline to creatine ratios in AD patients compared to controls [37] . This could be explained as an increase in the membrane turnover due to neuronal degeneration or to the increased demand of free choline to counterbalance the deficient acetylcholine production in AD. On the other hand, other authors failed to detect such an increase [47, 51] . [51] . In longitudinal studies it has been reported that metabolite annual percent change was able to differentiate control, MCI and AD patients [37] ; moreover, they could predict which patients with MCI would evolve to AD based on the metabolite annual percent change [37] . Other longitudinal studies have shown that MRS of occipital cortex is a valuable tool in predicting the conversion of MCI patients to AD [52] while presymptomatic mutation carriers of PS1 or APP showed metabolic changes before the expected onset of AD [53] . Contrary to the results obtained in human studies in AD [49, 50] , myo-inositol concentrations are not affected in Huntington's disease patients [26, 31] . [37] .
An important issue is whether AD could be differentiated from other neuropathologies, especially mild cognitive impairment (MCI). The MCI patients present with cognitive impairment beyond the one expected at their age and education and progress to AD with a rate of 10-15% per year. In this sense, MartinezBisbal and collaborators could differentiate between AD, vascular dementia, depression and MCI
Reproducibility of metabolite ratios may depend on physiological conditions and acquisition-related factors such as voxel positioning, but it has been suggested that metabolite ratio changes observed in longitudinal studies represent true changes over time
Because metabolomics does not rely on the measure of individual peaks but rather analyzes the whole of the spectra dataset and does not depend on any internal reference, it may actually improve the test-retest reproducibility of MRS.
MRS changes associated to AD vary in different brain regions. According to Modrego and collaborators spectra from occipital regions were able to predict conversion from MCI to probable AD, while differences in spectra from hypocampus or parietal cortex were not statistically significant [52] . Rami [47] . [54] . Using this approach it was found that NAA reduction in AD patients as compared to controls, is more severe in the medial temporal and parietal lobes while it was not changed in white matter or frontal lobe gray matter [54] . In the same article, these authors showed that by using MR imaging alone, they were able to classify AD from control with 89% accuracy, that increased up to 95% when adding spectroscopy (NAA), while no data were provided about the accuracy of spectroscopy alone [54] .
and collaborators obtained single voxel spectra from the posterior cingulate, the left temporal pole and the left posterior tempoparietal region, and they only found metabolic differences between MCI and AD in the left temporal pole
Chemical shift imaging allows researchers to obtain spectra simultaneously from various locations, making it ideal for studies involving regional differences. A standard MRS study on patients should include the acquisition of images to guide placing the voxels into the appropriate anatomic regions. It has been shown that the use of MRS combined with image analysis improves the classification of AD
MRS can be used to evaluate treatments both for AD and other neurodegenerative diseases and it may be important in phase II clinical studies for the evaluation of AD treatment [24] . This topic goes beyond the scope of this review; the interested reader is directed to an excellent work by Mueller and colleagues [24] .
Regarding the approaches involving pattern recognition studies, they have yet to be performed on MRS data from AD patients, although there is extensive data in brain tumour classification [22, 55] reviewed in [56] . Despite [57] [58] [59] .
Methodology: NMR metabolomics at work
Mass spectrometry (MS) coupled with chromatography (either gas or liquid) or NMR spectroscopy are the two main methodologies used in metabolomic studies, although other approaches have been used such as Fourier transform infra red (FTIR) spectroscopy or high-performance liquid chromatography (HPLC). MS is a very
Despite the low sensitivity of NMR spectroscopy, it has been successful in distinguishing mutants in yeast [14] , mouse models of neurodegenerative disease [42] or myocardial infarction in swine [60] among others. This may be due to the fact that metabolic networks are dominated by a few highly connected nodes or metabolites [61, 62] . In those systems, perturbations will be rapidly and widely spread throughout the network and thus many metabolites may be affected. Also, it may help that NMR is able to detect the most highly connected metabolites [62] .
NMR spectroscopy can be applied directly onto biofluids such as plasma [14] or urine [63] with little or no manipulation of the sample. In tissues, both dipolar coupling and diamagnetic susceptibility anisotropy are significant, giving rise to large line widths that reduce the quality of the spectra. This can be greatly improved by spinning the samples at the 'magic angle' (54.7) at which dipolar coupling is averaged to zero producing NMR spectra with line widths close to those obtainable in liquid samples [64] . Figure 2 shows [21] . On the other hand, they also provide with metabolic and functional information, and this information can be related to particular metabolic disorders [42] . Figure 3 shows a schematic representation of the main steps in any metabolomic analysis. Once the dataset is acquired, it is usually normalized within each spectrum and scaled along each variable [67] . Afterwards, unsupervised (Fig. 3D) 
